Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law Peptides: Legal and Regulatory Risks 503A Compounding Pharmacies Must Understand The FDA just announced that they're taking steps to lift restrictions on 12 peptides including BPC 157 and TB 500 making them accessible through compounding pharmacies again. This is a HUGE step Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP 1 compounding while @martymakary is photographed holding bootleg # Not all medical oversight is the same and wording matters., Terms like medical oversight and compounded are often used loosely, but true medical care involves licensed providers, proper FDA Removes 12 Peptides from 503A Category 2 Newtropin